December 2018 - Page 310 of 313

Canadian Stock Exchange News - December 3, 2018

MGX Minerals Reports High Grade Gold Mineralization at Depth at Fran Gold Project, British Columbia; Drilling to Re-Commence

VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) — MGX Minerals Inc. (“MGX” or the “Company”) (CSE: XMG / FKT: […]

NYSE Companies - December 3, 2018

NIO Inc. Provides November 2018 Monthly Delivery and Production Update, Announces NIO Day, December 15, 2018, as ES6 Launch Date

Delivered 3,089 ES8 vehicles in November 2018 Cumulative Production of ES8 exceeded 10,000 Milestone Announces NIO Day, December 15, 2018, […]

NASDAQ Companies - December 3, 2018

Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications

Novel small molecule FF-10158 targets integrin alphavbeta3 (avβ3) and alphavbeta5 (avβ5) receptors Expands theragnostic pipeline Potential broad application in the […]

NASDAQ Companies - December 3, 2018

Total voting rights

Total Voting Rights December 3, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with 5.6.1R of […]

TSX Venture News - December 3, 2018

Mkango Intersects Highest Grade Rare Earths Mineralisation to Date in Final Drill Results From the Songwe Hill Project in Malawi and Commences Resource Update

LONDON and VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) — Mkango Resources Ltd. (AIM / TSXV: MKA) (the “Company” […]

NYSE Companies - December 3, 2018

Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1

The AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx)[1], filing is supported by data from the START trial which demonstrated a […]

NASDAQ Companies - December 3, 2018

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

Detailed Phase 2 ITP data show clear correlation between IgG reduction, platelet count increase and reduction of bleeding events ITP […]

NASDAQ Companies - December 3, 2018

argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)

Regulated information – Inside information Collaboration to develop cusatuzumab in AML, MDS and other hematological malignancies in deal totaling up […]

NASDAQ Companies - December 2, 2018

Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-20-03 at the 2018 ASH Annual Meeting

– Complete Responses Observed in Three of Six Patients at Dose Level 1 and One of Three Patients at Dose […]

NASDAQ Companies - December 2, 2018

Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia

Data support opportunities to develop best-in-class, durable medicines for hemoglobinopathies CAMBRIDGE, Mass., Dec. 02, 2018 (GLOBE NEWSWIRE) — Editas Medicine, […]